Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa-Reference-Cited by-同舟云学术

Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa

Published:2018-11-12 Issue:11 Volume:68 Page:1932-1934
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Edgeworth Jonathan D¹,Merante Domenico²,Patel Sanjay²,Young Christopher³,Jones Paul⁴,Vithlani Seema⁵,Wyncoll Duncan³,Roberts Peter³,Jones Andrew³,Den Nagata Tsutae⁶,Ariyasu Mari⁶,Livermore David M⁷⁸,Beale Richard⁹

Affiliation:

1. Department of Infectious Diseases, Guy’s Hospital, Kings College London, London, United Kingdom

2. Shionogi Limited, Global Clinical Development Unit, London, United Kingdom

3. Intensive Care Unit, London Bridge Hospital, HCA International, London, United Kingdom

4. Microbiology Department, HCA International, London, United Kingdom

5. Pharmacy Department, London Bridge Hospital, HCA International, London, United Kingdom

6. Shionogi & Co., Ltd., Kitaku, Osaka, Japan

7. Norwich Medical School, University of East Anglia, United Kingdom

8. Antimicrobial Resistance & Healthcare Associated Infections Reference Unit, Public Health England, Colindale, London

9. School of Medicine, Guy’s Hospital, Kings College London, United Kingdom

Funder

UK government

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/68/11/1932/28653572/ciy963.pdf

Reference12 articles.

1. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study);Hackel;Antimicrob Agents Chemother,2017

2. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains;Kohira;Antimicrob Agents Chemother,2016

3. Cefiderocol: a novel siderophore cephalosporin;Choi;Expert Opin Investig Drugs,2018

4. Cefiderocol, a siderophore cephalosporin for gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment;Katsube;J Clin Pharmacol,2017

5. Pharmacokinetic/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function;Katsube;Antimicrob Agents Chemother,2017

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characteristics and outcomes in pseudomonas endocarditis: a systematic review of individual cases;Infection;2024-06-10

2. Cefiderocol: Clinical application and emergence of resistance;Drug Resistance Updates;2024-01

3. New advances in management and treatment of cardiac implantable electronic devices infections;Infection;2023-11-24

4. Dynamics of iron metabolism in patients with bloodstream infections: a time-course clinical study;Scientific Reports;2023-11-06

5. Successful use of prolonged cefiderocol monotherapy for the treatment of a complex pleural abscess caused by extensively drug-resistant (XDR) Pseudomonas aeruginosa;JAC-Antimicrobial Resistance;2023-09-04